Company: SLDE
Filing Date: 2025-06-09
Form Type: S-1/A
Source: 0001193125-25-137410
Chunk: 313

Company: Slide Insurance Holdings, Inc.
Filing Date: 2025-06-09
Form: S-1/A
Chunk 313
---
 “Clegg”) concurrently with the completion of our acquisition of Clegg.

6. In December 2022, we issued and sold 1,466,920 shares of our Series A preferred stock at a price of $13.64 per share to a group of
accredited investors for an aggregate purchase price of $20.0 million.

7. During the year ended December 31, 2022, we granted
760,000 options to purchase our common stock at a weighted-average exercise price of $5.03, pursuant to our Prior Plan.

8. During the year
ended December 31, 2023, we granted 1,350,000 options to purchase our common stock at a weighted-average exercise price of $7.59, pursuant to our Prior Plan.

9. On September 27, 2024, all of our warrants to purchase shares of our Series A preferred stock were exercised.

10. In December 2024, we issued 386,784 RSUs pursuant to our Prior Plan. 4,784 RSUs vest over one year ending on December 31, 2025. 200,000
RSUs vest ratably each month over 24 months commencing on January 1, 2025 and ending on December 31, 2026. For 182,000 RSUs, half vest on December 31, 2025, and half vest on December 31, 2026.

None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe the
offers, sales and issuances of the above securities were exempt from registration under the Securities Act (including under Regulation D or Regulation S promulgated thereunder) by virtue of Section 4(a)(2) of the Securities Act because the
issuance of securities to the recipients did not involve a public offering, or in reliance on Rule 701 because the transactions were pursuant to compensatory benefit plans or contracts relating to compensation as provided under such rule. The
recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed
upon the share certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising.

Item 16. Exhibits and Financial Statement Schedules